Live Updates: COVID-19 Cases
  • World 30,775,441
    World
    Confirmed: 30,775,441
    Active: 7,408,898
    Recovered: 22,408,874
    Death: 957,669
  • USA 6,932,705
    USA
    Confirmed: 6,932,705
    Active: 2,536,201
    Recovered: 4,193,222
    Death: 203,282
  • India 5,329,983
    India
    Confirmed: 5,329,983
    Active: 1,018,415
    Recovered: 4,225,803
    Death: 85,765
  • Brazil 4,497,434
    Brazil
    Confirmed: 4,497,434
    Active: 572,438
    Recovered: 3,789,139
    Death: 135,857
  • Russia 1,097,251
    Russia
    Confirmed: 1,097,251
    Active: 171,450
    Recovered: 906,462
    Death: 19,339
  • Peru 756,412
    Peru
    Confirmed: 756,412
    Active: 124,334
    Recovered: 600,795
    Death: 31,283
  • Mexico 688,954
    Mexico
    Confirmed: 688,954
    Active: 123,959
    Recovered: 492,192
    Death: 72,803
  • Spain 659,334
    Spain
    Confirmed: 659,334
    Active: 628,839
    Recovered: ?
    Death: 30,495
  • South Africa 657,627
    South Africa
    Confirmed: 657,627
    Active: 54,926
    Recovered: 586,844
    Death: 15,857
  • Chile 442,827
    Chile
    Confirmed: 442,827
    Active: 14,647
    Recovered: 415,981
    Death: 12,199
  • France 428,696
    France
    Confirmed: 428,696
    Active: 305,873
    Recovered: 91,574
    Death: 31,249
  • Iran 419,043
    Iran
    Confirmed: 419,043
    Active: 37,293
    Recovered: 357,632
    Death: 24,118
  • UK 385,936
    UK
    Confirmed: 385,936
    Active: 344,204
    Recovered: ?
    Death: 41,732
  • Bangladesh 347,372
    Bangladesh
    Confirmed: 347,372
    Active: 88,073
    Recovered: 254,386
    Death: 4,913
  • Saudi Arabia 329,271
    Saudi Arabia
    Confirmed: 329,271
    Active: 15,383
    Recovered: 309,430
    Death: 4,458
  • Pakistan 305,031
    Pakistan
    Confirmed: 305,031
    Active: 6,572
    Recovered: 292,044
    Death: 6,415
  • Turkey 299,810
    Turkey
    Confirmed: 299,810
    Active: 27,628
    Recovered: 264,805
    Death: 7,377
  • Italy 294,932
    Italy
    Confirmed: 294,932
    Active: 42,457
    Recovered: 216,807
    Death: 35,668
  • Germany 271,672
    Germany
    Confirmed: 271,672
    Active: 19,206
    Recovered: 243,000
    Death: 9,466
  • Canada 141,911
    Canada
    Confirmed: 141,911
    Active: 8,983
    Recovered: 123,723
    Death: 9,205
  • Netherlands 91,934
    Netherlands
    Confirmed: 91,934
    Active: 85,659
    Recovered: ?
    Death: 6,275
  • China 85,269
    China
    Confirmed: 85,269
    Active: 171
    Recovered: 80,464
    Death: 4,634
  • Australia 26,885
    Australia
    Confirmed: 26,885
    Active: 2,079
    Recovered: 23,962
    Death: 844
  • S. Korea 22,893
    S. Korea
    Confirmed: 22,893
    Active: 2,545
    Recovered: 19,970
    Death: 378
  • New Zealand 1,811
    New Zealand
    Confirmed: 1,811
    Active: 67
    Recovered: 1,719
    Death: 25

ELISA COVID-19 test kits can be used to determine infection exposure among public: Study

Author at TechGenyz Health
Test Kit
COVID-19 Test Kit Used In Laboratory. Credit: @ZenopaLtd/Twitter

Indigenously developed ELISA testing kits for COVID-19 have been found to be sensitive and specific for the detection of novel coronavirus antibodies in human serum samples and can be used for determining infection exposure among the general population, a study said.

The kit may be used to detect exposed immune-protected individuals, stated the study conducted by scientists of the Indian Council of Medical Research (ICMR) along with other collaborators and the result published in the Indian Journal of Medical Research (IJMR).

ELISA testing kit was found to be 92.37 per cent sensitive, 97.9 per cent specific, robust and reproducible. The positive and negative predictive values were 94.44 and 98.14 per cent respectively, it stated.

ICMR, the apex health research body, has been conducting a survey to assess the proportion of population exposed to novel coronavirus, including asymptomatic individuals as a part of which ELISA-based antibody tests would be used for data collection.

Researchers highlighted that for surveillance of the emerging and re-emerging viruses, serological assays have been widely recommended. Several IgM/IgG ELISA kits for COVID-19 are in varied stages of development.

However, validated and approved SARS-CoV-2 serological assays are lacking for case detection and are not included in WHO’s laboratory testing guidelines for COVID-19.

Due to non-availability of an indigenous, approved and cost-effective kit, an in-house ELISA was developed and validated for the detection of anti-SARS-CoV-2 human IgG antibodies, the study said.

A total of 513 blood samples were tested by the ELISA for COVID-19.

“Our findings suggested that this indigenous anti-SARS-CoV-2 human IgG-ELISA was sensitive and specific for the detection of IgG antibodies among individuals who have been exposed to coronavirus infection,” the study highlighted.

It can be used for ascertaining the seroprevalence against SARS-CoV-2 in a population and for epidemiological studies, it said.

“ELISA will be useful in screening healthcare workers, industry workers among others. The use of whole-cell antigen instead of recombinant nucleocapsid antigen or spike protein antigen provided a broad sensitivity to the assay. However, the assay performance needs to be assessed in a large cohort of related human/zoonotic coronaviruses,” the study added.

Such kits can be produced at low cost, are easy-to-use and affordable in resource-limited settings.

Career

Subscribe